Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.

Ruzzolini J, Laurenzana A, Andreucci E, Peppicelli S, Bianchini F, Carta F, Supuran CT, Romanelli MN, Nediani C, Calorini L.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):391-397. doi: 10.1080/14756366.2019.1706090.

PMID:
31865754
2.

Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells.

Peppicelli S, Ruzzolini J, Andreucci E, Bianchini F, Kontos F, Yamada T, Ferrone S, Calorini L.

Cancers (Basel). 2019 Aug 26;11(9). pii: E1249. doi: 10.3390/cancers11091249.

3.

Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.

Giorda CB, Cioffi G, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP; DYDA 2 Investigators.

Cardiovasc Drugs Ther. 2019 Oct;33(5):547-555. doi: 10.1007/s10557-019-06898-6.

PMID:
31418140
4.

Sequencing of NOTCH1 gene in an Italian population with bicuspid aortic valve: Preliminary results from the GISSI OUTLIERS VAR study.

Pileggi S, De Chiara B, Magnoli M, Franzosi MG, Merlanti B, Bianchini F, Moreo A, Romeo G, Russo CF, Rizzo S, Basso C, Martinelli L, Maseri A; VAR Study Group.

Gene. 2019 Oct 5;715:143970. doi: 10.1016/j.gene.2019.143970. Epub 2019 Jul 19.

PMID:
31330235
5.

Anoikis Resistance as a Further Trait of Acidic-Adapted Melanoma Cells.

Peppicelli S, Ruzzolini J, Bianchini F, Andreucci E, Nediani C, Laurenzana A, Margheri F, Fibbi G, Calorini L.

J Oncol. 2019 Jun 2;2019:8340926. doi: 10.1155/2019/8340926. eCollection 2019.

6.

Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer.

Bacci M, Lorito N, Ippolito L, Ramazzotti M, Luti S, Romagnoli S, Parri M, Bianchini F, Cappellesso F, Virga F, Gao Q, Simões BM, Marangoni E, Martin LA, Comito G, Ferracin M, Giannoni E, Mazzone M, Chiarugi P, Morandi A.

Cell Rep. 2019 Jul 2;28(1):104-118.e8. doi: 10.1016/j.celrep.2019.06.010.

7.

Identification of highly potent and selective MMP2 inhibitors addressing the S1' subsite with d-proline-based compounds.

Lenci E, Innocenti R, Di Francescantonio T, Menchi G, Bianchini F, Contini A, Trabocchi A.

Bioorg Med Chem. 2019 May 1;27(9):1891-1902. doi: 10.1016/j.bmc.2019.03.043. Epub 2019 Mar 22.

PMID:
30926311
8.

β3 -Adrenoceptor as a potential immuno-suppressor agent in melanoma.

Calvani M, Bruno G, Dal Monte M, Nassini R, Fontani F, Casini A, Cavallini L, Becatti M, Bianchini F, De Logu F, Forni G, la Marca G, Calorini L, Bagnoli P, Chiarugi P, Pupi A, Azzari C, Geppetti P, Favre C, Filippi L.

Br J Pharmacol. 2019 Jul;176(14):2509-2524. doi: 10.1111/bph.14660. Epub 2019 May 9.

PMID:
30874296
9.

Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools.

Bianchini F, De Santis A, Portioli E, Russo Krauss I, Battistini L, Curti C, Peppicelli S, Calorini L, D'Errico G, Zanardi F, Sartori A.

Nanomedicine. 2019 Jun;18:135-145. doi: 10.1016/j.nano.2019.02.015. Epub 2019 Mar 6.

PMID:
30849548
10.

Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma.

Bianchini F, Portioli E, Ferlenghi F, Vacondio F, Andreucci E, Biagioni A, Ruzzolini J, Peppicelli S, Lulli M, Calorini L, Battistini L, Zanardi F, Sartori A.

Cancer Lett. 2019 Apr 1;446:25-37. doi: 10.1016/j.canlet.2018.12.021. Epub 2019 Jan 11.

PMID:
30639534
11.

Oleuropein, the Main Polyphenol of Olea europaea Leaf Extract, Has an Anti-Cancer Effect on Human BRAF Melanoma Cells and Potentiates the Cytotoxicity of Current Chemotherapies.

Ruzzolini J, Peppicelli S, Andreucci E, Bianchini F, Scardigli A, Romani A, la Marca G, Nediani C, Calorini L.

Nutrients. 2018 Dec 8;10(12). pii: E1950. doi: 10.3390/nu10121950.

12.

β3-Adrenoreceptors Control Mitochondrial Dormancy in Melanoma and Embryonic Stem Cells.

Calvani M, Cavallini L, Tondo A, Spinelli V, Ricci L, Pasha A, Bruno G, Buonvicino D, Bigagli E, Vignoli M, Bianchini F, Sartiani L, Lodovici M, Semeraro R, Fontani F, De Logu F, Dal Monte M, Chiarugi P, Favre C, Filippi L.

Oxid Med Cell Longev. 2018 Nov 13;2018:6816508. doi: 10.1155/2018/6816508. eCollection 2018.

13.

SOX2 as a novel contributor of oxidative metabolism in melanoma cells.

Andreucci E, Pietrobono S, Peppicelli S, Ruzzolini J, Bianchini F, Biagioni A, Stecca B, Calorini L.

Cell Commun Signal. 2018 Nov 22;16(1):87. doi: 10.1186/s12964-018-0297-z.

14.

The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy.

Andreucci E, Ruzzolini J, Peppicelli S, Bianchini F, Laurenzana A, Carta F, Supuran CT, Calorini L.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):117-123. doi: 10.1080/14756366.2018.1532419.

15.

Gold Nanoparticles Functionalized with RGD-Semipeptides: A Simple yet Highly Effective Targeting System for αV β3 Integrins.

Maggi V, Bianchini F, Portioli E, Peppicelli S, Lulli M, Bani D, Sole RD, Zanardi F, Sartori A, Fiammengo R.

Chemistry. 2018 Aug 14;24(46):12093-12100. doi: 10.1002/chem.201801823. Epub 2018 Jul 16.

PMID:
29923243
16.

Stereodivergent synthesis of 5-aminopipecolic acids and application in the preparation of a cyclic RGD peptidomimetic as a nanomolar αVβ3 integrin ligand.

Sernissi L, Ricci L, Scarpi D, Bianchini F, Arosio D, Contini A, Occhiato EG.

Org Biomol Chem. 2018 May 9;16(18):3402-3414. doi: 10.1039/c8ob00534f.

PMID:
29675532
17.

Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis.

Andreucci E, Peppicelli S, Carta F, Brisotto G, Biscontin E, Ruzzolini J, Bianchini F, Biagioni A, Supuran CT, Calorini L.

J Mol Med (Berl). 2017 Dec;95(12):1341-1353. doi: 10.1007/s00109-017-1590-9. Epub 2017 Sep 19.

PMID:
28929255
18.

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.

Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7.

PMID:
28917544
19.

Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.

Ruzzolini J, Peppicelli S, Andreucci E, Bianchini F, Margheri F, Laurenzana A, Fibbi G, Pimpinelli N, Calorini L.

Cancer Lett. 2017 Nov 1;408:43-54. doi: 10.1016/j.canlet.2017.08.010. Epub 2017 Aug 18.

PMID:
28826720
20.

Synthesis and conformational analysis of peptides embodying 2,3-methanopipecolic acids.

Ricci L, Sernissi L, Scarpi D, Bianchini F, Contini A, Occhiato EG.

Org Biomol Chem. 2017 Aug 16;15(32):6826-6836. doi: 10.1039/c7ob01617d.

Supplemental Content

Loading ...
Support Center